News about Global Pharma

Asahi Kasei Bioprocess and Axolabs Forge Alliance to Propel Oligonucleotide Therapeutics

Asahi Kasei Bioprocess and Axolabs Forge Alliance to Propel Oligonucleotide Therapeutics

Oligonucleotide therapies offer a targeted approach to treating diseases by modulating gene expression, splicing, and protein production.

Global Pharma | 15/04/2024 | By Abha |  935

Awshad Rolls Out Brain-Boosting Nutritional Supplement Myndshroom

Awshad Rolls Out Brain-Boosting Nutritional Supplement Myndshroom

Awshad, a pioneering medical cannabis wellness startup, has rolled out its latest innovation, Myndshroom.

Global Pharma | 15/04/2024 | By Aishwarya |  1179

Thermo Fisher Introduces CTS OpTmizer One SFM to Boost Cell Therapy Manufacturing

Thermo Fisher Introduces CTS OpTmizer One SFM to Boost Cell Therapy Manufacturing

Thermo Fisher Scientific has introduced the Gibco CTS OpTmizer One Serum-Free Medium (CTS OpTmizer One SFM).

Global Pharma | 15/04/2024 | By Aishwarya |  830

AbbVie Announces Late-Breaking Data at AAN Supporting Long-Term Safety and Efficacy of Atogepant for Preventive Treatment of Migraine

AbbVie Announces Late-Breaking Data at AAN Supporting Long-Term Safety and Efficacy of Atogepant for Preventive Treatment of Migraine

The overall long-term safety results were consistent with the known safety profile of atogepant in chronic and episodic migraine, and no new safety signals were identified.

Global Pharma | 12/04/2024 | By Manvi |  693

Telix Pharmaceuticals Completes Acquisition of ARTMS

Telix Pharmaceuticals Completes Acquisition of ARTMS

Telix Pharmaceuticals Ltd. has completed the acquisition of ARTMS Inc.
<br />

Global Pharma | 12/04/2024 | By Aishwarya |  803

Corvia Medical Responds to Trial Data, Emphasizes Patient Selection in Heart Failure Therapy

Corvia Medical Responds to Trial Data, Emphasizes Patient Selection in Heart Failure Therapy

This therapy is currently under investigation in the global RESPONDER-HF trial of the Corvia® Atrial Shunt.

Global Pharma | 12/04/2024 | By Abha |  596

Lamassu Biotech Receives FDA Approval for Phase 1/2a Clinical Trials of Novel Cancer Therapy

Lamassu Biotech Receives FDA Approval for Phase 1/2a Clinical Trials of Novel Cancer Therapy

This approval paves the way for the initiation of Phase 1/2a clinical trials for SA53-OS, a therapy designed to combat locally advanced metastatic p53 wild-type tumors.

Global Pharma | 12/04/2024 | By Abha |  835

Orna Therapeutics Appoints Frank Neumann as CMO

Orna Therapeutics Appoints Frank Neumann as CMO

Orna Therapeutics, a biotechnology company dedicated to designing and delivering a new class of fully engineered circular RNA therapeutics (oRNA®) announced that Frank Neumann, M.D., Ph.D., will join the Company as Chief Medical Officer.

Global Pharma | 11/04/2024 | By Manvi |  652

Sen-Jam Pharmaceutical and KVK-Tech to Provide CMC for Anti-Inflammatory Injectable

Sen-Jam Pharmaceutical and KVK-Tech to Provide CMC for Anti-Inflammatory Injectable

Sen-Jam Pharmaceutical has entered a third strategic collaboration with KVK-Tech.

Global Pharma | 11/04/2024 | By Aishwarya |  1086

Vertex Signs Agreement to Acquire Alpine Immune Sciences

Vertex Signs Agreement to Acquire Alpine Immune Sciences

Vertex Pharmaceuticals has signed a definitive agreement with Alpine Immune Sciences, a biotechnology company focused on discovering and developing innovative, protein-based immunotherapies.

Global Pharma | 11/04/2024 | By Aishwarya |  1045

 
 

 

 

We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.

More information: Privacy Policy

 pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members